针对突变 KRAS 诱导免疫原性细胞死亡。
Targeting Mutant KRAS for Immunogenic Cell Death Induction.
机构信息
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France.
出版信息
Trends Pharmacol Sci. 2020 Jan;41(1):1-3. doi: 10.1016/j.tips.2019.11.004. Epub 2019 Dec 6.
Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRAS inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.
尽管体细胞 KRAS 突变在人类肿瘤中很常见，但直到最近才有一种抑制突变 KRAS 的抑制剂在临床上可用。Canon 及其同事描述了一种临床可用的 KRAS 抑制剂驱动免疫原性癌细胞死亡的能力，因此它成为免疫检查点抑制剂的有前途的组合伙伴。
Zotero 插件